Fierce Pharma

9 of the Top 10 Pharma Manufacturers Partner with Redi Health to Lead the Next-Generation Patient Experience

The pharmaceutical industry is reaching a turning point in patient support. | Life sciences leaders say patient support is ...
FiercePharma

AI in Patient Support Services: Five Early Learnings

While digital technologies have reshaped many industries, healthcare is one of the last to rely on faxes and phone calls. This holds true for workflows in physician offices and hospitals, which are ...
Business Wire

Aurion Biotech Doses First Patients in ASTRA Phase 3 Study, Evaluating AURN001 in Patients with Corneal Edema Secondary to Corneal Endothelial Dysfunction

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a ...
Nasdaq

Krystal Biotech, Inc. Doses First Patient in Phase 3 Trial Evaluating KB803 for Corneal Abrasion Treatment in Dystrophic Epidermolysis Bullosa Patients

Krystal Biotech, Inc. has initiated its Phase 3 clinical trial, named IOLITE, to evaluate KB803, a gene therapy designed to treat and prevent corneal abrasions in patients with dystrophic ...
Seeking Alpha

PDS Biotech outlines VERSATILE-003 amendment targeting interim PFS with approximately 250 patients

Dr. Frank Bedu-Addo (President, CEO & Director) said the quarter’s “major focus was on advancing our clinical programs,” and handed the program update to the CMO, pointing to “significant progress” on ...
Nasdaq

Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker ...

78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of serum or tumor CEACAM1 subgroup 61% reduction is risk of death and 72% reduction in ...